Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134315 · ClinicalTrials.gov registry record
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
A clinical trial, sponsored by AbbVie (prior sponsor, Abbott).
- Terminated
- Registry status
- 61
- Enrollment target
NCT01134315 is a clinical trial that was terminated before completion, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 61 participants.
The verdict
NCT01134315 was terminated before completion, sponsored by AbbVie (prior sponsor, Abbott).
- TERMINATED
- Registry status
- 61 participants
- Enrollment target
Study Summary
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT). Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).
Interventions
- DRUG Paricalcitol
- DRUG Calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134315
The ClinicalTrials.gov registry entry for NCT01134315 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paricalcitol is the first listed.
NCT01134315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134315 about?
NCT01134315 is a clinical study titled "Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice". The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT). Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the inc...
What is the current status of trial NCT01134315?
This trial is currently terminated. The enrollment target is 61 participants. The study started on 2010-06. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01134315?
The interventions under investigation include: Paricalcitol (DRUG), Calcitriol (DRUG).
Who is sponsoring clinical trial NCT01134315?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.